marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-13-2024
Tenax Therapeutics Financial Ratios 2011-2024 | TENX
Annual Financial Ratios Tenax Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
0.2 | 0.0 | -0.6 | 1.7 | -1.0 | -0.3 | -1.0 | -1.2 | -7.3 | -2.2 | -0.7 | -3.1 | -4.4 |
P/S |
- | - | - | - | - | - | - | - | 2079.4 | 152.1 | 5.1 | 118.7 | 142.0 |
EPS |
- | - | -1.6 | -0.9 | -1.4 | -9.0 | -6.3 | -31.2 | -0.5 | -2.7 | -6.3 | -0.6 | -0.5 |
EV (Enterprise Value) |
-4.94 M | -90.2 K | 16.7 M | 10.9 M | 6.11 M | -8.97 M | 8.43 M | 51 M | 111 M | -3.87 M | 10.4 M | 51.9 M | 51.5 M |
EBITDA per Share |
27.6 | 386 | 1.59 | 1.33 | -1.36 | -4.4 | -6.52 | -13.8 | -9.71 | -35.2 | -58.1 | -123 | -170 |
EV/EBITDA |
0.5 | 1.1 | -0.4 | 1.5 | -0.8 | -2.3 | -6.9 | 0.9 | -1.8 | -6.1 | -5.0 | ||
PEG |
0.0 | 0.0 | 0.01 | 0.01 | -0.01 | 0.01 | -0.01 | 0.0 | -0.09 | -0.04 | -0.01 | 0.09 | -0.26 |
P/B |
0.2 | 0.1 | 4.8 | 3.7 | 2.2 | 0.2 | 1.0 | 3.2 | 1.5 | 0.5 | -3.5 | -142.4 | -12.3 |
P/CF |
-0.2 | -0.0 | -1.9 | -1.8 | -1.1 | -0.3 | -0.7 | -3.5 | -10.4 | -4.7 | -1.2 | -5.8 | -5.2 |
ROE % |
95.22 | 740.11 | -765.06 | 212.98 | -222.51 | -57.88 | -99.53 | -256.25 | -19.99 | -23.58 | 529.56 | 4540.56 | 280.53 |
ROA % |
65.99 | 324.49 | -541.94 | 143.42 | -131.88 | -51.09 | -89.37 | -188.19 | -16.98 | -20.92 | -296.03 | -379.35 | -357.53 |
ROCE % |
- | 709.90 | 739.08 | 207.41 | -223.21 | -58.56 | -103.65 | -113.10 | -17.58 | -18.28 | -388.73 | -806.91 | -1388.24 |
Current Ratio |
3.3 | 1.8 | 3.4 | 3.2 | 2.4 | 8.5 | 8.0 | 2.2 | 3.9 | 22.9 | 1.0 | 0.8 | 0.7 |
DSO |
- | - | - | - | - | - | - | - | 566.4 | 83.6 | 160.2 | 43.1 | 157.2 |
DIO |
- | - | - | - | - | - | - | - | - | - | 839.9 | 593.7 | 428.6 |
DPO |
- | - | - | - | - | - | - | - | - | 1156.1 | 8273.2 | 3865.6 | 1481.1 |
Operating Cycle |
- | - | - | - | - | - | - | - | - | 83.6 | 1000.1 | 636.8 | 585.9 |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | -1072.6 | -7273.1 | -3228.8 | -895.2 |
All numbers in USD currency
Quarterly Financial Ratios Tenax Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | - | - | - | - | - | - | - | - | - | - | - | -0.15 | -0.1 | -1.64 | - | -0.18 | -0.23 | -0.38 | - | -0.33 | -0.28 | -0.33 | - | -1.05 | -1.28 | -0.84 | - | -0.87 | -2.12 | -2.33 | - | -0.15 | -0.17 | -0.19 | -0.1 | -0.1 | -0.13 | -0.11 | -0.43 | -0.14 | -0.22 | - | -1.45 | -1.23 | -1.23 | -2.06 | -0.26 | -0.97 | -0.05 | -0.12 | -0.11 | -0.12 | -0.12 | -0.12 |
EBITDA per Share |
- | 1.88 | - | - | 0.09 | 0.05 | 0.07 | - | 0.1 | 0.11 | 0.11 | - | 0.15 | 0.11 | 1.64 | - | 0.18 | 0.23 | 0.38 | - | 0.34 | 0.29 | 0.34 | - | 1.07 | 1.3 | 0.86 | - | 0.94 | 2.14 | 2.49 | - | 0.16 | 0.17 | -0.2 | -0.11 | -0.11 | -0.13 | -0.11 | -0.23 | -0.14 | -0.15 | -0.09 | -0.95 | -0.41 | -0.41 | -0.74 | -0.07 | -0.32 | -0.02 | -0.05 | 0.12 | -0.08 | 0.09 | 0.11 |
ROE % |
92.39 | 105.79 | 57.14 | -0.75 | 73.02 | 129.31 | 95.50 | -137.85 | -85.37 | -106.66 | -181.20 | -831.37 | -879.38 | -979.86 | -909.55 | -151.80 | -92.86 | 14.09 | 107.19 | 148.51 | 161.56 | 115.67 | 84.84 | 39.05 | 52.94 | 53.79 | 71.55 | 84.40 | 109.33 | 120.37 | 113.82 | 20.73 | 15.98 | -13.78 | -46.69 | -20.44 | -26.75 | -27.14 | -26.28 | -23.88 | 137.94 | 19.37 | -288.15 | -159.25 | 527.51 | 3334.83 | 3891.29 | 4801.45 | 4042.58 | 1437.69 | 1012.63 | -179.48 | 78.64 | -181.08 | -77.04 |
ROA % |
80.51 | 93.12 | 51.57 | -0.50 | 61.04 | 106.00 | 79.63 | -45.51 | -2.89 | -21.80 | -47.07 | -537.61 | -569.94 | -644.89 | -616.63 | -102.23 | -67.29 | -0.03 | 58.90 | 88.02 | 99.54 | 76.12 | 62.45 | 34.46 | 46.94 | 47.90 | 64.09 | 75.79 | 94.10 | 99.93 | 89.62 | 15.22 | 11.29 | -11.02 | -35.73 | -16.92 | -22.86 | -23.41 | -23.01 | -21.18 | -90.61 | -167.02 | -222.55 | -290.82 | -335.43 | -298.44 | -268.83 | -284.83 | -225.33 | -245.77 | -167.97 | 81.22 | -64.41 | 47.44 | 98.18 |
ROCE % |
- | - | - | - | 72.05 | 144.10 | 185.52 | 267.83 | 318.87 | 297.85 | 371.30 | 925.47 | 972.32 | 968.13 | 898.40 | 148.11 | 207.08 | 219.21 | 221.54 | 150.50 | 163.70 | 117.93 | 86.50 | 39.64 | 54.39 | 55.94 | 73.84 | 88.09 | 114.34 | 125.84 | 119.16 | 20.22 | 15.04 | -16.36 | -49.81 | -21.68 | -24.52 | -24.72 | -23.60 | -21.36 | 86.10 | 17.32 | -164.68 | -72.36 | 43.22 | 1294.02 | 1588.08 | 1982.85 | 1822.97 | 701.42 | 467.48 | -137.02 | 55.14 | -126.96 | -65.19 |
Current Ratio |
39.0 | 6.1 | 7.1 | 3.3 | 19.7 | 17.1 | 15.4 | 1.8 | 6.0 | 5.3 | 1.8 | 3.4 | 5.3 | 2.0 | 3.1 | 3.1 | 3.1 | 3.1 | 3.1 | 2.5 | 2.5 | 2.5 | 2.5 | 8.5 | 8.5 | 8.5 | 8.5 | 9.8 | 9.8 | 9.8 | 9.8 | 3.8 | 3.8 | 3.8 | 3.8 | 5.8 | 5.8 | 5.8 | 5.8 | 9.3 | 7.7 | 9.3 | 8.9 | 0.7 | 2.9 | 1.2 | 0.6 | 0.9 | 1.0 | 0.9 | 0.9 | - | 0.6 | 0.8 | 0.4 |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 97.5 | - | - | - | 16.1 | 132.3 | 443.9 | 127.9 | 11.3 | 3.6 | 3.3 | 2.2 | 13.0 | 17.1 | 80.1 | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 97.5 | - | - | - | 16.1 | 132.3 | 443.9 | 127.9 | 11.3 | 3.6 | 3.3 | 2.2 | 13.0 | 17.1 | 80.1 | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 97.5 | - | - | - | 16.1 | 132.3 | 443.9 | 127.9 | 11.3 | 3.6 | 3.3 | 2.2 | 13.0 | 17.1 | 80.1 | - |
All numbers in USD currency